OCA 5 mg ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
94Primary sclerosing cholangitis1

94. Primary sclerosing cholangitis


Clinical trials : 142 Drugs : 113 - (DrugBank : 37) / Drug target genes : 19 - Drug target pathways : 139
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-002205-38-IT
(EUCTR)
02/12/201512/02/2018A Study of Obeticholic Acid (OCA) in Patients with Primary Sclerosing CholangitisA Phase 2, Randomized, Double-Blind, Placebo-Controlled,Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects with Primary Sclerosing Cholangitis - AESOP (Assessment of Efficacy and Safety of OCA in PSC) Primary Sclerosing Cholangitis
MedDRA version: 20.0;Level: SOC;Classification code 10019805;Term: Hepatobiliary disorders;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: OCA 1,5 mg
Product Code: INT-747, OCA
INN or Proposed INN: ACIDO OBETICOLICO
Other descriptive name: ACIDO OBETICOLICO
Product Name: OCA 5 mg
Product Code: INT-747, OCA
INN or Proposed INN: ACIDO OBETICOLICO
Other descriptive name: ACIDO OBETICOLICO
INTERCEPT PHARMACEUTICALS INC.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
75Phase 2United States;Italy